Stock 2105 LAEKNA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Laekna, Inc. Stock

Equities

2105

KYG5340S1093

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:03 2024-05-23 am EDT 		5-day change 1st Jan Change
7.42 HKD +4.21% Intraday chart for Laekna, Inc. -0.27% -62.71%
04:07am US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
02:15am Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI

Financials

Sales 2022 280K 38.67K 302K Sales 2023 470K 64.9K 507K Capitalization 7.06B 974M 7.61B
Net income 2022 -782M -108M -843M Net income 2023 -369M -50.96M -398M EV / Sales 2022 * -
Net cash position 2022 295M 40.7M 318M Net cash position 2023 723M 99.78M 779M EV / Sales 2023 13,475 x
P/E ratio 2022 *
-
P/E ratio 2023
-10.8 x
Employees 89
Yield 2022 *
-
Yield 2023
-
Free-Float 8.78%
More Fundamentals * Assessed data

Chart Laekna, Inc.

Dynamic Chart

Latest news about Laekna, Inc.

US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8% MT
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer CI
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug MT
Lekna, Inc. Obtains IND Approval from the CDE for LAE102 CI
Laekna Scores FDA Nod for Obesity Drug LAE102 MT
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102 CI
Laekna Shrinks Loss in Fiscal 2023 MT
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug MT
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration CI
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities MT
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102 CI
Laekna, Inc. Announces Management Changes CI
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34% MT
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China CI
More news

Press releases Laekna, Inc.

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer PR
Laekna Releases 2023 ESG Report PR
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024 PR
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results PR
Laekna, Inc. (2105.HK) Announces Interim Results 2023 PR
More press releases

Quotes and Performance

1 day+4.21%
1 week-0.27%
Current month+20.06%
1 month+23.05%
3 months+114.45%
6 months-66.95%
Current year-62.71%
More quotes

Highs and lows

1 week
6.95
Extreme 6.95
8.07
1 month
5.54
Extreme 5.54
8.08
Current year
3.15
Extreme 3.15
19.76
1 year
3.15
Extreme 3.15
26.45
3 years
3.15
Extreme 3.15
26.45
5 years
3.15
Extreme 3.15
26.45
10 years
3.15
Extreme 3.15
26.45
More quotes

Quotes

Date Price Change Volume
24-05-23 7.42 +4.21% 11 163 000
24-05-22 7.12 -1.25% 3,238,500
24-05-21 7.21 -6.97% 1,804,000
24-05-20 7.75 +5.30% 3,537,500
24-05-17 7.36 -1.08% 7,087,000

Delayed Quote Hong Kong S.E., May 23, 2024 at 04:08 am EDT

More quotes

Company Profile

Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer and liver disease. The Company is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The Company's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The Company mainly conducts its businesses in China, the United States, Europe and South Korea.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LAEKNA, INC. Stock Laekna, Inc.
-62.71% 356M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.10% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.70% 106B
BIONTECH SE Stock BioNTech SE
-4.33% 24.69B
ARGENX SE Stock argenx SE
-2.33% 21.97B
GENMAB A/S Stock Genmab A/S
-6.03% 19.27B
BEIGENE, LTD. Stock BeiGene, Ltd.
-11.64% 17.56B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.36% 17.32B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.38% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.86% 12.13B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2105 Stock